Reneo Pharmaceuticals
Biotechnology ResearchCalifornia, United States11-50 Employees
Reneo Pharmaceuticals is now OnKure Therapeutics, Inc.!
Insights
Strategic Partnership Potential The recent merger with OnKure, Inc. positions Reneo Pharmaceuticals as a clinical-stage biopharmaceutical company focusing on precision medicines in oncology. This merger opens up opportunities for strategic partnerships and collaborations in the oncology therapeutic space.
Market Expansion Opportunity Reneo Pharmaceuticals' pivot towards precision medicines in oncology, along with their existing expertise in rare genetic mitochondrial diseases, presents a unique opportunity for market expansion. Leveraging their diversified portfolio can help target a broader customer base and explore new market segments.
Innovative Product Development The development of a peroxisome proliferation activated receptor delta agonist program, including compound HPP593, showcases Reneo Pharmaceuticals' commitment to innovative product development. This program opens doors for introducing novel therapies and attracting partnerships for further research and commercialization.
Investor Attraction Potential With successful financing events, including a recent $55 million public offering, Reneo Pharmaceuticals has demonstrated strong investor interest. This financial stability not only indicates growth potential but also presents an opportunity to attract new investors interested in the biotechnology sector.
Key Personnel Advantage The addition of Roshawn Blunt to Reneo Pharmaceuticals' Board of Directors brings valuable expertise and connections to the team. Leveraging the knowledge and networks of key personnel like Roshawn Blunt can open doors for strategic alliances, business development opportunities, and industry collaborations.
Similar companies to Reneo Pharmaceuticals
Frontier Medicines
113
$10M$50MDeep Genomics
104$10M$50Minsitro
327$50M$100MValo Health
155$10M$50MA2A Pharmaceuticals
10$10MRelay Therapeutics
281$10M$50MAbCellera
585$100M$1BEnvisagenics
52$10MSchrödinger
966$100M$1BBoundless Bio
85$10M$50M
Reneo Pharmaceuticals Tech Stack
Media & News
Reneo Pharmaceuticals's Email Address Formats
Reneo Pharmaceuticals uses at least 2 format(s):
| Reneo Pharmaceuticals Email Formats | Percentage |
| FLast@reneopharma.com | 100% |
Frequently Asked Questions
Where is Reneo Pharmaceuticals's headquarters located?
Reneo Pharmaceuticals's main headquarters is located at 18575 Jamboree Rd 275 Irvine, California 92612 US. The company has employees across 3 continents, including North AmericaEuropeAsia. What is Reneo Pharmaceuticals's stock symbol?
Reneo Pharmaceuticals is a publicly traded company; the company's stock symbol is OKUR. What is Reneo Pharmaceuticals's official website and social media links?
Reneo Pharmaceuticals's official website is onkure.com and has social profiles on LinkedIn.How much revenue does Reneo Pharmaceuticals generate?
As of November 2024, Reneo Pharmaceuticals's annual revenue reached $3.8M. What is Reneo Pharmaceuticals's SIC code NAICS code?
Reneo Pharmaceuticals's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).How many employees does Reneo Pharmaceuticals have currently?
As of November 2024, Reneo Pharmaceuticals has approximately 18 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Operating Officer: M. C.Chief Development Officer (cdo): A. H.Chief Development Officer: A. H.. Explore Reneo Pharmaceuticals's employee directory with LeadIQ.What industry does Reneo Pharmaceuticals belong to?
Reneo Pharmaceuticals operates in the Biotechnology Research industry. What is Reneo Pharmaceuticals's email format?
Reneo Pharmaceuticals's email format typically follows the pattern of . Find more Reneo Pharmaceuticals email formats with LeadIQ. How much funding has Reneo Pharmaceuticals raised to date?
As of November 2024, Reneo Pharmaceuticals has raised $55M in funding. The last funding round occurred on May 03, 2023 for $55M.
Company Overview
- Headquarters
- 18575 Jamboree Rd 275 Irvine, California 92612 US
- Website
- onkure.com
- SIC Code
- 8733 - Noncommercial Research Organizations
- Stock Symbol
- OKUR
- NAICS Code
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Employees
- 11-50
Media & News
Funding & Financials
- $55M
Reneo Pharmaceuticals has raised a total of $55M of funding over 4 rounds. Their latest funding round was raised on May 03, 2023 in the amount of $55M.
- $10M
Reneo Pharmaceuticals's revenue is in the range of $10M
Funding & Financials
- $55M
Reneo Pharmaceuticals has raised a total of $55M of funding over 4 rounds. Their latest funding round was raised on May 03, 2023 in the amount of $55M.
- $10M
Reneo Pharmaceuticals's revenue is in the range of $10M
Company Leadership
M. C.Chief Operating Officer
A. H.Chief Development Officer (cdo)- A. H.Chief Development Officer
- W. J.Chief Business Officer
- W. J.Chief Business Officer
Employee Directory
- W. J.Chief Business Officer
- W. J.Chief Business Officer
H. B.Vice President, Global Tech Ops & Cmc- C. S.Vice President Of Global Regulatory Affairs
- A. F.Vice President, Head Of Global Legal Affairs
1-888-653-2347 
support@leadiq.com © LeadIQ, Inc. All rights reserved.
